Chronic hepatitis B virus infected patient
Conditions
Interventions
None listed
Sponsors
Department of Gastroenterology and Hepatology, Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are 20 years of age or older at the time of obtaining informed consent 2. Patients who are informed and have provided written informed consent to participate in the study prior to study initiation 3. Patients with chronic HBV who do not meet any of the following exclusion criteria 4. Patients receiving nucleos(t)ide analogues or plan to be treated with nucleos(t)ide analogues
Exclusion criteria
Exclusion criteria: 1. Patients with difficult to manage cardiac disease 2. Patients who have a history of allergic reaction by nucleos(t)ide analogues 3. Patients treated with contraindicated drug together with nucleos(t)ide analogues 4. Patients by whom doctor in charge has determined to be inappropriate as a subject 5. Patients by whom principal investigator has determined to be inappropriate as a subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The degree of HBV-DNA and HBsAg decline 1 year after administration of nucleos(t)ide analugues | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The degree of HBV-DNA and HBsAg decline 3, 5, 10 years after administration of nucleos(t)ide analugues 2. Relevalence between IL28B SNPs and HBsAg decline 3. Relevalence between serum IFN-lambda3 and HBsAg decline 4. Relevalence between emergence of resistant associated variant and antiviral effect 5. efficacy of improvement of hepatic fibrosis 6. efficacy of improvement of AST/ALT | — |
Countries
Japan
Contacts
Public ContactGoki Suda
Hokkaido University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed